BioNTech SE has announced its all-stock acquisition of CureVac, marking a significant step in its strategic expansion in the field of mRNA-based cancer immunotherapy. The transaction, approved by both companies' management and supervisory boards, aims to enhance BioNTech's research, development, manufacturing, and commercialization capabilities. By integrating CureVac's research and manufacturing site in Tübingen, BioNTech seeks to leverage complementary scientific capabilities and proprietary technologies to accelerate the development of transformative mRNA-based medicines. The acquisition is expected to close in 2025, subject to customary closing conditions and regulatory approvals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.